Abstract
Pulling vaccine efficacy and effectiveness (VE) outcomes from 17 reports of 9 different vaccine products and through sequence analysis, we found that genetic mismatch explained sizable variations in VE. The findings suggested the potential need of timely optimizing vaccine antigens as new dominant viral strains emerge.
Competing Interest Statement
M.H.W and B.C.Y.Z are shareholders of Beth Bioinformatics Co., Ltd. B.C.Y.Z is a shareholder of Health View Bioanalytics Ltd. All other authors declare no competing interests.
Funding Statement
This work was supported by the National Natural Science Foundation of China [31871340, 71974165], the Hong Kong Health and Medical Research Fund [INF-CUHK-1], and the Chinese University of Hong Kong Direct Grant [4054456, 4054524].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethical approval or individual consent was not applicable.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data used in this work are publicly available.
